Robert Weber, MD
Family Medicine · Watsonville, CANPI 1235207184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 25.5% of the total. Reporting peaked in 2019 at $327 and has fallen 71.5% since, to $93 in 2025.
Across 44 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$160
- Amgen$91
- Incyte Corporation$81
- Boehringer Ingelheim$79
- Exact Sciences$37
- Merck$34
- plus $146 from 7 others
Across 10 payments — averaging $1720.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$17K
What the payments were for
- Food & beverage$62399%
- Education$51%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 21 | $160 |
| Amgen | 5 | $91 |
| Incyte Corporation | 4 | $81 |
| Boehringer Ingelheim | 4 | $79 |
| Exact Sciences | 2 | $37 |
| Merck | 1 | $34 |
| Pharmacosmos Therapeutics Inc. | 1 | $29 |
| ADC Therapeutics America, Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $15 |
How this compares
$629 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 260 | $303,899 |
| TrulicityDulaglutide | 87 | $130,799 |
| MounjaroTirzepatide | 80 | $90,087 |
| EliquisApixaban | 91 | $85,061 |
| JanuviaSitagliptin Phosphate | 37 | $59,489 |
| RybelsusSemaglutide | 18 | $47,743 |
| OzempicSemaglutide | 26 | $41,858 |
| XareltoRivaroxaban | 32 | $31,102 |
| TradjentaLinagliptin | 25 | $29,405 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $24,426 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $24,241 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $21,792 |
| FarxigaDapagliflozin Propanediol | 16 | $15,576 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,853 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $10,821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $79 | $333,303285 claims |
| Novo NordiskRybelsus, Ozempic | $19 | $89,60144 claims |
| MerckJanuvia, Janumet Xr | $34 | $70,30953 claims |
| Johnson & JohnsonXarelto | $160 | $31,10232 claims |
| AstraZenecaFarxiga | $17 | $15,57616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.
Other family medicine in Watsonville
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.